Association of carotid intima-media thickness with cardiovascular risk factors and patient outcomes in advanced chronic kidney disease: the RRI-CKD study

Alan Hinderliter1, Robin L. Padilla2, Brenda W. Gillespie2, Nathan W. Levin3, Peter Kotanko3, Margaret Kiser1, Fredric Finkelstein4, Sanjay Rajagopalan5, and Rajiv Saran2,6

1Department of Internal Medicine, University of North Carolina, Chapel Hill, NC, 2University of Michigan-Kidney Epidemiology and Cost Center, Ann Arbor, MI, 3Renal Research Institute, New York, NY, 4Hospital of St. Raphael Yale University, New Haven, CT, 5Department of Cardiovascular Medicine, Ohio State University, Columbus, OH, and 2Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA

Abstract. Background: Chronic kidney disease (CKD) is associated with accelerated atherosclerosis and an increased risk of adverse cardiovascular disease (CVD) outcomes. The relationships of intima-media thickness (IMT), a measure of subclinical atherosclerosis, with traditional and nontraditional risk factors and with adverse outcomes in CKD patients are not well-established. Methods: IMT, clinical characteristics, cardiovascular risk factors, and clinical outcomes were measured in 198 subjects from the Renal Research Institute (RRI) CKD study, a four-center prospective cohort of patients with estimated glomerular filtration rate (eGFR) ≤ 50 mL/min/1.73 m² not requiring renal replacement therapy. Results: The patients averaged 61 ± 14 years of age; the mean eGFR was 29 ± 12 mL/min/1.73 m². Maximum IMT was more closely associated with traditional cardiovascular risk factors, including age, diabetes, dyslipidemia, and systolic blood pressure, than with nontraditional risk factors or with eGFR. Higher values of maximum IMT were also independently associated with clinical CVD and with other markers of subclinical CVD. Maximum IMT ≥ 2.6 mm was predictive of the composite endpoint of CVD events and death (hazard ratio (HR): 5.47 (95% confidence interval (CI): 2.97 – 10.07, p < 0.0001)) but was not related to progression to end-stage renal disease (HR: 1.67 (95% CI: 0.74 – 3.76, p = 0.21)). Conclusion: In patients with advanced predialysis CKD, higher maximum IMT was associated with traditional cardiovascular risk factors, CVD, and other markers of subclinical CVD and was an independent predictor of cardiovascular events and death. Additional research is needed to examine the clinical utility of IMT in the risk stratification and clinical management of patients with CKD.

Introduction

Chronic kidney disease (CKD) is associated with an increased risk of adverse cardiovascular disease (CVD) outcomes. In patients with kidney failure on dialysis, mortality due to CVD is 10 – 30 times that in the general population [1]. Individuals with lesser degrees of renal dysfunction are also predisposed to cardiovascular events. Several recent reports from prospective population-based studies suggest that mild-to-moderate renal insufficiency predicts cardiovascular morbidity and mortality [2, 3, 4, 5]. Indeed, patients with CKD are more likely to die of CVD than to develop renal failure [6, 7, 8].

In patients with CKD there is a high prevalence of traditional CVD risk factors, such as advanced age, diabetes, and hypertension [9, 10, 11, 12, 13]. Some studies, however, indicate that the relationships between estimated glomerular filtration rate (eGFR) and CVD morbidity, and mortality are independent of these characteristics [14, 15, 16]. These observations have led to the suggestion that “nontraditional” risk factors,
such as inflammation, abnormal calcium and phosphorous metabolism, anemia, hyperparathyroidism, hypoalbuminemia, and albuminuria may contribute to the risk of CVD in CKD patients.

Assessment of the intima-media thickness (IMT) of the carotid artery is a reproducible, safe, and non-invasive method of detecting subclinical atherosclerosis. Previous cross-sectional studies in cohorts without CKD have demonstrated associations between carotid IMT and both cardiovascular risk factors and the presence of CVD [17, 18, 19, 20]. Several large observational studies have also shown that carotid IMT is a predictor of coronary heart disease events that remains significant after adjustment for traditional risk factors [21, 22, 23, 24, 25, 26]. The relationship between IMT and risk for cardiovascular events in the context of a dominant risk factor such as CKD has been examined in only a few studies.

We examined carotid IMT in patients with advanced pre-dialysis CKD enrolled in the Renal Research Institute (RRI)-CKD study to 1) assess the relationships between IMT and traditional risk factors, nontraditional risk factors, and other markers of subclinical CVD; and 2) evaluate the relationship of subclinical atherosclerosis to adverse clinical outcomes in this population. We hypothesized that IMT would be correlated with both traditional and nontraditional CVD risk factors as well as other markers of cardiac disease, and would predict both cardiovascular events and progression to end-stage renal disease.

Methods

Patient population

The RRI-CKD study is a four-center, prospective, observational cohort study involving adult patients with moderate-to-severe CKD, not on dialysis, enrolled between 06/2000 and 02/2006 (n = 834). Details of the study have been described previously [27]. Eligibility criteria included age ≥ 18 years and estimated glomerular filtration rate (eGFR) ≤ 50 mL/min by the Cockcroft-Gault formula. When enrollment eGFR was recalculated by the abbreviated Modification of Diet in Renal Disease equation, values were greater than 50 mL/min/1.73 m² in a few cases (n = 5). At enrollment and follow-up visits, data on demographic characteristics, anthropometric measures, cause of CKD, symptoms, laboratory values, and medications were collected.

From January 1, 2003 onwards, a subset of individuals from the RRI-CKD cohort voluntarily consented to undergo blood, urine, and non-invasive cardiovascular studies, including measurement of carotid IMT. In addition, 199 patients were newly recruited into the CVD sub-study. While these participants were similar to the original RRI-CKD cohort participants with respect to age, diabetes, hypertension, history of CVD, race, gender, and medication use, significantly higher mean eGFR (32 vs. 24) was observed. Figure 1 displays the patient recruitment flow into this analysis. This paper is based on patients with carotid IMT data (n = 198).

Patients who enrolled in the cardiovascular sub-study from the original RRI-CKD study (n = 149) were generally healthier than those who did not; they were younger (mean
age 58 vs. 64 years), had a higher mean eGFR (27 vs. 25 mL/min/1.73 m²), and were less likely to have diabetes (30% vs. 42%) or a history of CVD (37% vs. 58%). The difference between the CVD sub-study and RRI-CKD participants was likely due to patient self-selection into a study that involved substantial testing and patient burden. This selection seems especially likely because the characteristics of the newly recruited CVD sub-study patients were similar to the consenters from the original RRI-CKD cohort. Finally, of the 348 participants enrolled into the cardiovascular sub-study, 150 declined measurement of IMT. These participants were similar to the 198 subjects who underwent this procedure.

The Institutional Review Boards of the participating centers approved the protocol, and a written informed consent was obtained for all study subjects.

Clinical and laboratory data

Baseline variables collected at the time of enrollment in the RRI-CKD study included the following: demographic characteristics (e.g., age, sex, and race), clinical measurements (e.g., height, weight, blood pressure, heart rate), clinical comorbidities (e.g., diabetes mellitus, hypertension, dyslipidemia, and history of tobacco use), and laboratory parameters (e.g., serum creatinine, serum calcium, serum phosphorous, serum albumin, hematocrit, intact parathyroid hormone (iPTH), lipid levels, and urine albumin-to-creatinine ratio). Blood pressure was measured in duplicate after 5 minutes of rest in the seated position using an automated, oscillometric device (Omron model HEM-412C), and the results averaged. Blood specimens were acquired after a 12-hour fast. Diabetes was defined as a fasting glucose ≥ 126 mg/dL or use of insulin or other medication for glycemic control. Hypertension was defined by a systolic BP ≥ 140 mmHg or use of antihypertensive agents. Dyslipidemia was defined as total cholesterol ≥ 240 mg/dL, LDL-cholesterol ≥ 130 mg/dL, HDL-cholesterol ≤ 40 mg/dL, or treatment with a statin. Smoking status was determined by self-report.

Measures of subclinical cardiovascular disease

To insure uniformity of technique, study coordinators and sonographers at each site were trained in procedures for carotid artery ultrasound imaging and other measures of subclinical CVD at the University of Michigan data coordinating centers. Images were analyzed at the core vascular laboratory at the University of Michigan.

Carotid intima-media thickness (IMT)

Longitudinal images of the right and left common carotid arteries, carotid bulbs, and internal carotid arteries were acquired with a high-resolution B-mode ultrasound transducer and recorded for subsequent analysis at the core laboratory. Using electronic calipers, IMT was measured as the distance between the luminal-intima interface and the medial-adventitial interface at multiple points of the near and far walls of the distal 1 cm segments of the common carotid arteries, the carotid bulbs, and the internal carotid arteries. The mean IMT was calculated as the average of all IMT measurements; the mean of maximum IMT was calculated as the average of maximum wall thickness measurements from each region. The reproducibility of IMT measurement in the core laboratory has been described in a prior publication [28].

Other measures of subclinical cardiovascular disease

Left ventricular mass was calculated as described by Devereux et al. [29], from echocardiographic measurements of end-diastolic internal dimension and wall thicknesses. Left ventricular mass index (LVMI) was derived by correcting left ventricular mass for body surface area (LVMI = left ventricular mass/body surface area). Arterial stiffness was quantified as the carotid-femoral pulse wave velocity (PWV) using an ATCOR (version 7.0) device, as described previously [30]. Coronary calcium was measured using a 4-slice LightSpeed QXi and quantified as the Agatston score using coro-
Flow-mediated dilation of the brachial artery (FMD) was assessed by measuring changes in arterial diameter induced by reactive hyperemia and calculated as the percent change from baseline [32]. Arterial diameters at end-diastole were measured using customized software (Brachial Tools, Medical Imaging Applications, LLC, Coralville IA, USA). Measures of heart rate variability (HRV) were based on 24-hour ambulatory ECG recordings, analyzed using SyneTec Holter analysis software, version 1.20 (Ela Medical, Paris, France), as described in a prior publication [33].

Clinical follow-up

Follow-up of patients ended on December 31, 2006; all 348 patients, except 7 who were lost to follow-up, were followed for at least 10 months. All outcomes were ascertained on an ongoing basis by study coordinators, who had no knowledge of IMT results, and were based on regular review of electronic health records, direct patient contact in clinic, and periodic telephone communication. Endpoints included a composite of death or CVD events, including coronary events (myocardial infarction, coronary revascularization procedures), cerebrovascular events (stroke or transient ischemic attack), new onset heart failure, sudden cardiac death, or development of peripheral vascular disease requiring revascularization or amputation; and progression to end-stage renal disease (ESRD), defined as initiation of dialysis or pre-emptive renal transplantation.

Statistical methods

Descriptive data of the study cohort are expressed as mean ± standard deviation for continuous variables (or median (interquartile range) for skewed variables) and as proportions for categorical variables. The relationships of IMT with demographic and anthropomorphic variables, clinical characteristics, traditional and non-traditional coronary risk factors, eGFR, and other measures of subclinical CVD were assessed by Pearson correlations. Multiple linear regressions were performed to assess predictors of carotid IMT, and Cox regression was used to analyze time to event outcomes. The method of best subsets was used to guide model selection process, with the R-squared selection criterion used for linear regression and the likelihood score ($\chi^2$) statistic criterion used for Cox regression [34]. Skewed variables were natural log transformed and a p-value < 0.05 was considered significant. Martingale residuals obtained from Cox regression models were examined to assess the correct functional form of IMT (IMT $\geq$ 2.6 mm). All analyses were conducted using SAS, version 9.2 (SAS Institute Inc., Cary, NC USA).
Results

Baseline patient characteristics

Demographic and clinical characteristics of the study cohort are summarized in Table 1. The mean age of the study participants was 61 ± 14 years, with a range of 18 – 89 years. The mean eGFR was 29 ± 12 mL/min/1.73 m². Nearly equal numbers had stage 3 (n = 86) and stage 4 (n = 88) CKD; 24 had stage 5 CKD. Diabetes (30%), hypertension (99%), and CVD (42%) were common comorbidities. Laboratory results and indices of subclinical CVD are shown in Table 2.

Association of IMT with baseline clinical characteristics

The median values for maximum and mean IMT were 1.21 (range: 0.48 – 4.91) mm, and 0.85 (0.44 – 2.25) mm, respectively. Analyses using maximum and mean IMT measurements yielded similar results; therefore, only those using maximum IMT are described in this manuscript.

The correlations between IMT and eGFR, traditional risk factors, novel risk factors and other measures of CVD are summarized in Table 3. No correlation was observed between IMT and eGFR. Of traditional cardiovascular risk factors, age was most closely correlated with IMT; male gender, diabetes, current or former tobacco use, dyslipidemia, and higher systolic blood pressure (BP) were also strongly associated with increased IMT. The relationships of diabetes, dyslipidemia, and systolic BP with IMT remained significant after adjustment for age. Serum albumin was the only nontraditional risk factor associated with IMT.

Higher values of IMT were significantly associated with clinical CVD and with other markers of subclinical CVD. Patients with a clinical history of coronary artery disease, heart failure, cerebrovascular disease, and peripheral arterial disease had significantly higher values of IMT than those without known heart disease, independent of age. Figure 2 displays the positive correlations of IMT with (a) PWV, (b) LVMI, and (c) coronary calcification score, as well as (d) the negative correlation with heart rate variability (low/high frequency ratio). These relationships remained statistically significant after correcting for age. There was no significant correlation of IMT with brachial artery FMD.

Table 4 displays results of a multivariable model examining traditional risk factors and presence of CKD as predictors of maximum IMT. Age, diabetes, dyslipidemia, systolic BP, and clinical CVD were strong independent predictors of carotid IMT.

Association of IMT with clinical outcomes

Patients were followed for a median of 2.4 years following enrollment into the car-
diovascular sub-study. During this time, 47 patients had at least one CVD event (n = 38) and/or died (n = 20), and 45 patients reached ESRD.

Maximum IMT ≥ 2.6 mm was associated with a composite endpoint of CVD events and death (HR: 5.47 (95% CI: 2.97 – 10.07, p < 0.0001)) but was not associated with the development of end-stage renal disease (HR: 1.67 (95% CI: 0.74 – 3.76, p = 0.21)). The survival curves shown in Figure 3 illustrate the higher probability of CVD events or death with greater maximum IMT levels. After adjustment for age, white race, diabetes, and clinical history of CVD, IMT ≥ 2.6 mm remained a strong predictor of composite endpoint (HR: 2.75 (95% CI: 1.41 – 5.38, p = 0.0031)). Maximum IMT also remained independently associated with the composite endpoint in models that included nontraditional risk factors, FMD, PWV, LVMI, or measures of HRV.

Discussion

The principal findings of our study include the following: 1) patients in our cohort with advanced CKD had a high prevalence of coronary risk factors and clinical CVD; 2) IMT was more closely associated with traditional cardiovascular risk factors, such as age, diabetes, dyslipidemia, systolic BP, and tobacco use, than with nontraditional risk factors or with eGFR; 3) higher IMT was associated with clinical CVD and with other markers of subclinical disease; and 4) higher IMT predicted cardiovascular events, independent of traditional and nontraditional risk factors and prevalent CVD.

Our finding that IMT is more closely associated with traditional risk factors than with eGFR is consistent with the results from several previous population studies [13, 35, 36]. Studies that have examined factors associated with carotid atherosclerosis in patients with advanced, pre-dialysis CKD have yielded inconsistent results. Shoji et al. [37], measured IMT in 110 non-diabetic pre-dialysis patients with CKD (serum creatinine ≥ 1.5 mg/dL), 345 non-diabetic patients with ESRD treated with maintenance hemodialysis, and 302 healthy controls. IMT was similar in patients with CKD and ESRD, and
greater than in healthy controls. In the CKD group, IMT correlated significantly with age and tobacco use, and the relationship with systolic BP was of borderline significance; there was no correlation of IMT with creatinine, total cholesterol, or HDL cholesterol. Kawamoto et al. [38], examined IMT in 428 men and 582 women from a single center in Japan; 49% had stage 2 CKD, and 32% had stage 3 CKD. Age, systolic blood pressure, LDL cholesterol, HDL cholesterol and eGFR were significant predictors of IMT in both genders, and eGFR was a significant independent predictor after adjusting for other risk factors. In a cohort of Chinese patients with stages 3 or 4 CKD, Szeto et al. [39], found significant associations of IMT with age, LDL-cholesterol, diabetes, and C-reactive protein, but not with systolic BP, cigarette smoking, or kidney function. Lemos et al. [40], also noted a significant correlation of IMT with C-reactive protein, as well as age and systolic BP, but not with eGFR in patients with predominantly stages 3 or 4 CKD.

Our examination of IMT in the RRI-CKD study mirrors the results of our previously published analyses from this cohort demonstrating that changes in arterial compliance and coronary calcification are explained by conventional CVD risk factors rather than by the degree of renal dysfunction or by abnormalities in mineral metabolism. Sengstock et al. [30], examined PWV in 264 patients from the RRI-CKD cohort and 149 subjects without previously recognized CKD. Age, systolic BP, diabetes, body mass index, and heart rate were independent predictors of PWV. A statistically significant relationship of eGFR with PWV was also demonstrated, but eGFR explained less than 1% of PWV variability in models adjusting for age, systolic BP, diabetes, body mass index, and heart rate. Similarly, Dellegrottaglie et al. [31], studied determinants of coronary artery calcium in 106 patients from the RRI cardiovascular cohort who underwent multi-detector computed tomography. Coronary artery calcification was predicted by age, gender, and diabetes, but not by parameters related to renal function, including eGFR, calcium, phosphorous, i-PTH, hemoglobin, and albumin.

Carotid IMT predicts clinical cardiovascular events, independent of traditional cardiovascular risk factors in the general population [21, 22, 23, 24, 25]. In the USE intima-media thickness (USE-IMT) global meta-analysis project using individual participant data from prospective cohort studies (n = 45,828), adjusted common carotid IMT was positively related to myocardial infarction and stroke with a hazard ratio per 0.1-mm difference of common IMT of 1.12 (95%

| Table 3. Pearson correlations of maximum carotid intima-media thickness (IMT; natural log-scale) with traditional and nontraditional risk factors and biomarkers of cardiovascular risk (n = 198). |
|-----------------|--------|----------------|
| Demographic/anthropomorphic measures | | |
| Age (years) | 0.61 | < 0.001 |
| Male gender | 0.14 | 0.044 |
| Black race | 0.09 | 0.213 |
| Body mass index (kg/m²) | 0.05 | 0.445 |
| Indices of renal function | | |
| Serum creatinine (mg/dL) | −0.02 | 0.829 |
| Estimated glomerular filtration rate (mL/min/1.73 m²) | −0.04 | 0.541 |
| Blood urea nitrogen (mg/dL) | 0.19 | 0.008 |
| Clinical CVD | | |
| Any clinical CVD | 0.42 | < 0.001 |
| Cerebrovascular disease | 0.16 | 0.020 |
| Coronary artery disease | 0.36 | < 0.001 |
| Peripheral arterial disease | 0.25 | < 0.001 |
| Heart failure | 0.35 | < 0.001 |
| Traditional coronary risk factors | | |
| Diabetes | 0.32 | < 0.001 |
| Hypertension | 0.04 | 0.564 |
| Current or former smoker | 0.19 | 0.009 |
| Dyslipidemia | 0.20 | 0.006 |
| Total cholesterol (mg/dL) | −0.13 | 0.084 |
| Low-density lipoprotein (mg/dL) | −0.14 | 0.053 |
| High-density lipoprotein (mg/dL) | −0.01 | 0.901 |
| Triglycerides (mg/dL) | 0.01 | 0.895 |
| Systolic blood pressure (mmHg) | 0.32 | < 0.001 |
| Pulse pressure (mmHg) | 0.43 | < 0.001 |
| Heart rate (bpm) | −0.01 | 0.903 |
| Novel coronary risk factors | | |
| Serum total calcium (mg/dL) | 0.00 | 0.967 |
| Serum phosphorous (mg/dL) | 0.05 | 0.517 |
| Serum albumin (mg/dL) | −0.18 | 0.013 |
| Hematocrit (%) | −0.10 | 0.169 |
| Intact parathyroid hormone (ng/mL) | 0.00 | 0.980 |
| C-reactive protein (mg/L) | 0.11 | 0.126 |
| Urine albumin/creatinine ratio (mg/g) | 0.03 | 0.683 |
| Markers of subclinical CVD | | |
| Flow-mediated dilation (%) | −0.06 | 0.397 |
| Pulse wave velocity (m/s) | 0.46 | < 0.001 |
| Left ventricular mass index (g/m²) | 0.36 | < 0.001 |
| Coronary calcification score | 0.46 | < 0.001 |
| Heart rate variability: low/high frequency ratio | −0.30 | < 0.001 |
| Heart rate variability: SDNN (ms) | 0.00 | 0.979 |

SDNN = standard deviation of all normal R-R (NN) intervals; †Natural log-scale.
Carotid IMT in CKD

CI 1.09–1.14) for women and 1.08 (95% CI 1.05–1.11) for men [26]. Increased IMT is also associated with adverse outcomes in dialysis patients [41, 42] and was a predictor of fatal and nonfatal cardiovascular events in subjects with stages 4 to 5 CKD enrolled in the atherosclerosis and folic acid supplementation trial [43]. The associations of IMT with prevalent CVD and with CVD events in patients with advanced pre-dialysis CKD have not been extensively studied. Adesun et al. [44], demonstrated that IMT was a predictor of self-reported CVD, with a c-statistic of 0.64, in an ancillary study of the chronic renal insufficiency cohort (CRIC) study. Szeto et al. [39] followed 203 Chinese patients with stage 3 or 4 CKD for an average of 52 months. As noted in our cohort, IMT was an independent predictor of survival free from cardiovascular events, but not of progression to ESRD. Our study extends the findings of Szeto et al. [39], by demonstrating in a multi-racial cohort an association of IMT with cardiovascular events that is independent of traditional CVD risk factors.

Previous studies of atherosclerosis in population-based cohorts have emphasized the prognostic importance of carotid plaque [21, 45]. Our analysis of outcomes using maximum IMT suggests that plaque is also a powerful predictor of adverse outcomes in patients with CKD. Mean of maximum IMT was calculated from the maximum intima-media thickness of each imaged segment, which reflects the maximum height of any plaque in that segment. Thus, high values for maximum IMT suggest the presence of plaque. A marked increase in mean maximum IMT (≥ 2.6 mm) was associated with more than a five-fold increase in the risk of cardiovascular events in our cohort, and remained significantly associated with poor outcomes after adjustment for CVD and other risk factors.

Our study has limitations which are important to consider when interpreting the results. The absence of a clear association of IMT with eGFR may be in part due to the narrow range of values for eGFR in our subjects. It may also reflect a survival bias in this referred cohort of CKD patients; patients with more extensive atherosclerosis (and greater IMT) may have died before reaching advanced stages of CKD. Treatment with medications may also obscure relationships between risk factors and IMT. The majority of our subjects were prescribed anti-hypertensive agents, and nearly half were treated with a statin. Our cross-sectional analyses do not take into account the duration of exposure to risk factors. Although carotid IMT is independently associated with a risk of cardiovascular events, it is an imperfect measure of atherosclerosis and may not necessarily reflect disease in other vascular beds. Finally, creatinine was measured in different laboratories (at the individual sites) and GFR was estimated, not measured.

We conclude that carotid IMT reflects clinical and subclinical CVD in patients with
advanced pre-dialysis CKD and is associated with traditional cardiovascular risk factors, especially older age, hypertension, diabetes and dyslipidemia. IMT is a predictor of adverse cardiovascular events independent of traditional and novel risk factors in this population. Additional research is needed to examine the clinical utility of IMT in the risk stratification and clinical management of patients with CKD.

**Acknowledgment**

The study was funded by the Renal Research Institute, New York, NY. We are grateful to all study coordinators and to Kerri Briesmiester, Project Manager, for training the study coordinators.

**Conflict of interest**

The study was conducted with the support of the Michigan Clinical Research Unit, University of Michigan, funded by the NIH grant UL1RR024986.

Dr. Nathan Levin and Dr. Peter Kotanko hold stock in Fresenius Medical Care.

**References**

[1] Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32 (Suppl 3): S112-S119. CrossRef PubMed

[2] Manjunath G, Tighiouart H, Coresh J, MacLeod B, Salem DN, Griffith JL, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003; 63: 1121-1129. CrossRef PubMed

[3] Munter P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002; 13: 745-753. PubMed

[4] Matsashita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375: 2073-2081. CrossRef PubMed

[5] Tomelll M, Munter P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, James MT, Hemmelgarn BR. Alberta Kidney Disease Network. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012; 380: 807-814. CrossRef PubMed

[6] Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA. The Hypertension Detection and Follow-up Program Cooperative Group. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. Hypertension. 1989; 13 (Suppl): 180-193. CrossRef PubMed

[7] Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005; 16: 489-495. CrossRef PubMed

[8] Dalrymple LS, Katz R, Kestenbaum B, Shlipak MG, Sarnak MJ, Stehman-Breen C, Seliger S, Siscovick D, Newsman AB, Fried L. Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med. 2011; 26: 379-385. CrossRef PubMed

[9] Calleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999; 56: 2214-2219. CrossRef PubMed

[10] Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001; 134: 629-636. CrossRef PubMed

[11] Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003; 41: 47-55. CrossRef PubMed

[12] Ruliope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, Zanchetti A. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol. 2001; 12: 218-225. PubMed

[13] Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM. Cardiovascular disease risk status in elderly persons with renal insufficiency. Kidney Int. 2002; 62: 997-1004. CrossRef PubMed

[14] Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol. 2002; 13: 1918-1927. CrossRef PubMed

[15] Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MW, Teehan BP, Levey AS. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000; 58: 353-362. CrossRef PubMed

[16] Sarnak MJ, Coronado BE, Greene T, Wang SR, Kusek JW, Beck GJ, Levey AS. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol. 2002; 57: 327-335. CrossRef PubMed

[17] Poi A, Tremoli E, Colombo A, Sistori M, Pignoli P, Paolotti R. Ultrasonographic measurement of the common carotid artery wall thickness in hy-
percholesterolomic patients. A new model for the quantification and follow-up of preclinical atherosclerosis in living human subjects. Atherosclerosis. 1988; 70: 253-261. CrossRef PubMed

[18] O’Leary DH, Polak JF, Krommal RA, Kittner SJ, Bond MG, Wolfson SK Jr, Bommer W, Price TR, Gardin JM, Savage PJ. The CHS Collaborative Research Group. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. Stroke. 1992; 23: 1752-1760. CrossRef PubMed

[19] Mannioni T, Konishi M, Baba S, Nishi N, Terao A. Prevalence of asymptomatic carotid atherosclerotic lesions detected by high-resolution ultrasonography and its relation to cardiovascular risk factors in the general population of a Japanese city: the Suita study. Stroke. 1997; 28: 518-525. CrossRef PubMed

[20] Bots ML, Breslau PJ, Briët E, de Bruyn AM, van Vliet HJ, van den Ouweland FA, de Jong PT, Hofman A, Grobbee DE. Cardiovascular determinants of carotid artery disease. The Rotterdam Elderly Study. Hypertension. 1997; 19: 717-720. CrossRef PubMed

[21] Polak JF, Pencina MJ, Pencina KM, O'Donnell CJ, Wolf PA, D’Agostino RBS Sr. Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med. 2011; 365: 213-221. CrossRef PubMed

[22] Chambless LE, Heiss G, Folsom AR, Rosamond W, Sklo M, Sharrett AR, Clegg LX. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol. 1997; 146: 483-494. CrossRef PubMed

[23] O’Leary DH, Polak JF, Krommal RA, Manolio TA, Burke GL, Wolfson SK Jr. Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999; 340: 14-22. CrossRef PubMed

[24] Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation. 1997; 96: 1432-1437. CrossRef PubMed

[25] Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, Azcn SP. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998; 128: 262-269. CrossRef PubMed

[26] Den Ruijter HM, Peters SA, Anderson TJ, Britton AR, Dekker JM, Eijkemans MJ, Engstrom G, Evans GW, de Graaf J, Grobbee DE, Hedblad B, Hofman A, Holeiwijn S, Iekeda A, Kavousi M, Kitagawa K, Kitamura A, Koffijberg H, Lonn EM, Lorenz MW, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA. 2012; 308: 796-803. CrossRef PubMed

[27] Perlman RL, Kiser M, Finkelstein F, Eisele G, Roys E, Liu L, Burrows-Hudson S, Port F, Mansana JM, Bailie G, Rajagopalan S, Saran R. The longitudinal chronic kidney disease study: a prospective cohort study of predialysis renal failure.
Canziani ME. Intima-media thickness is associated with inflammation and traditional cardiovascular risk factors in non-dialysis-dependent patients with chronic kidney disease. Nephron Clin Pract. 2010; 115: c189-c194. CrossRef PubMed

Kato A, Takita T, Maruyama Y, Kamagai H, Hishida A. Impact of carotid atherosclerosis on long-term mortality in chronic hemodialysis patients. Kidney Int. 2003; 64: 1472-1479. CrossRef PubMed

Benedetto FA, Mallamaci F, Tripepi G, Zoccali C. Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients. J Am Soc Nephrol. 2001; 12: 2458-2464. PubMed

Zoungas S, Cameron JD, Kerr PG, Wolfe R, Muske C, McNeil JJ, McGrath BP. Association of carotid intima-medial thickness and indices of arterial stiffness with cardiovascular disease outcomes in CKD. Am J Kidney Dis. 2007; 50: 622-630. CrossRef PubMed

Adeseun GA, Xie D, Wang X, Joffe MM, Mohler ER III, Townsend RR, Budoff M, Rosas SE. Carotid plaque, carotid intima-media thickness, and coronary calcification equally discriminate prevalent cardiovascular disease in kidney disease. Am J Nephrol. 2012; 36: 342-347. CrossRef PubMed

Nambi V, Chambless L, Folsom AR, He M, Hu Y, Mosley T, Volcik K, Boerwinkle E, Ballantyne CM. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol. 2010; 55: 1600-1607. CrossRef PubMed